Literature DB >> 20951421

Curing hepatitis C with pills: a step toward global control.

David L Thomas1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20951421      PMCID: PMC4083467          DOI: 10.1016/S0140-6736(10)61497-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

1.  Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

Authors:  John G McHutchison; Eric J Lawitz; Mitchell L Shiffman; Andrew J Muir; Greg W Galler; Jonathan McCone; Lisa M Nyberg; William M Lee; Reem H Ghalib; Eugene R Schiff; Joseph S Galati; Bruce R Bacon; Mitchell N Davis; Pabak Mukhopadhyay; Kenneth Koury; Stephanie Noviello; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; Mark S Sulkowski
Journal:  N Engl J Med       Date:  2009-07-22       Impact factor: 91.245

2.  Surprisingly small effect of antiviral treatment in patients with hepatitis C.

Authors:  Yngve Falck-Ytter; Hemangi Kale; Kevin D Mullen; Steedman A Sarbah; Lucian Sorescu; Arthur J McCullough
Journal:  Ann Intern Med       Date:  2002-02-19       Impact factor: 25.391

3.  Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.

Authors:  Paul Y Kwo; Eric J Lawitz; Jonathan McCone; Eugene R Schiff; John M Vierling; David Pound; Mitchell N Davis; Joseph S Galati; Stuart C Gordon; Natarajan Ravendhran; Lorenzo Rossaro; Frank H Anderson; Ira M Jacobson; Raymond Rubin; Kenneth Koury; Lisa D Pedicone; Clifford A Brass; Eirum Chaudhri; Janice K Albrecht
Journal:  Lancet       Date:  2010-08-06       Impact factor: 79.321

4.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

5.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Authors:  John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

6.  Market uptake of new antiviral drugs for the treatment of hepatitis C.

Authors:  Beate Lettmeier; Nikolai Mühlberger; Ruth Schwarzer; Gaby Sroczynski; Davene Wright; Stefan Zeuzem; Uwe Siebert
Journal:  J Hepatol       Date:  2008-06-02       Impact factor: 25.083

7.  Public health impact of antiviral therapy for hepatitis C in the United States.

Authors:  Michael L Volk; Rachel Tocco; Sameer Saini; Anna S F Lok
Journal:  Hepatology       Date:  2009-12       Impact factor: 17.298

  7 in total
  13 in total

Review 1.  Global epidemiology and burden of HCV infection and HCV-related disease.

Authors:  Aaron P Thrift; Hashem B El-Serag; Fasiha Kanwal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-12-07       Impact factor: 46.802

2.  Impact of hepatitis coinfection on hospitalization rates and causes in a multicenter cohort of persons living with HIV.

Authors:  Trevor A Crowell; Kelly A Gebo; Ashwin Balagopal; John A Fleishman; Allison L Agwu; Stephen A Berry
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

3.  Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action.

Authors:  Noémie Calland; Marie-Emmanuelle Sahuc; Sandrine Belouzard; Véronique Pène; Pierre Bonnafous; Ahmed Atef Mesalam; Gaspard Deloison; Véronique Descamps; Sevser Sahpaz; Czeslaw Wychowski; Olivier Lambert; Priscille Brodin; Gilles Duverlie; Philip Meuleman; Arielle R Rosenberg; Jean Dubuisson; Yves Rouillé; Karin Séron
Journal:  J Virol       Date:  2015-07-22       Impact factor: 5.103

Review 4.  Epidemiology and natural history of HCV infection.

Authors:  Behzad Hajarizadeh; Jason Grebely; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-02       Impact factor: 46.802

Review 5.  Highly active anti-hepatitis C therapy: seven lessons from HIV.

Authors:  David L Thomas
Journal:  Antivir Ther       Date:  2012-10-05

6.  Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting.

Authors:  André Seidenberg; Thomas Rosemann; Oliver Senn
Journal:  BMC Infect Dis       Date:  2013-01-08       Impact factor: 3.090

Review 7.  Hepatitis C in HIV-infected individuals: cure and control, right now.

Authors:  David L Thomas; Dennis Leoutsakas; Tomas Zabransky; M Suresh Kumar
Journal:  J Int AIDS Soc       Date:  2011-05-08       Impact factor: 5.396

8.  Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013.

Authors:  Gilles Wandeler; Marion Schlauri; Marie-Eve Jaquier; Janine Rohrbach; Karin J Metzner; Jan Fehr; Juan Ambrosioni; Matthias Cavassini; Marcel Stöckle; Patrick Schmid; Enos Bernasconi; Olivia Keiser; Luisa Salazar-Vizcaya; Hansjakob Furrer; Andri Rauch; V Aubert; M Battegay; E Bernasconi; J Böni; H C Bucher; C Burton-Jeangros; A Calmy; M Cavassini; G Dollenmaier; M Egger; L Elzi; J Fehr; J Fellay; H Furrer; C A Fux; M Gorgievski; H Günthard; D Haerry; B Hasse; H H Hirsch; M Hoffmann; I Hösli; C Kahlert; L Kaiser; O Keiser; T Klimkait; R Kouyos; H Kovari; B Ledergerber; G Martinetti; B Martinez de Tejada; K Metzner; N Müller; D Nadal; D Nicca; G Pantaleo; A Rauch; S Regenass; M Rickenbach; C Rudin; F Schöni-Affolter; P Schmid; J Schüpbach; R Speck; P Tarr; A Telenti; A Trkola; P Vernazza; R Weber; S Yerly
Journal:  Open Forum Infect Dis       Date:  2015-03-25       Impact factor: 3.835

9.  HCV Ag quantification as a one-step procedure in diagnosing chronic hepatitis C infection in Cameroon: the ANRS 12336 study.

Authors:  Léa Duchesne; Richard Njouom; Frédéric Lissock; Gishlaine Flore Tamko-Mella; Sandrine Rallier; Lila Poiteau; Alexandre Soulier; Stéphane Chevaliez; Guy Vernet; Nicolas Rouveau; Jean-Michel Pawlotsky; Pierre-Marie Girard; Karine Lacombe
Journal:  J Int AIDS Soc       Date:  2017-05-15       Impact factor: 5.396

Review 10.  Epidemiology and Elimination of HCV-Related Liver Disease.

Authors:  Pierre Pradat; Victor Virlogeux; Eric Trépo
Journal:  Viruses       Date:  2018-10-06       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.